2 hours ago
12
Spyre Therapeutics stock remains one of the more explosive biotech stories of the past year. The stock surged roughly 565% over twelve months and touched a fresh three-year high. On Tuesday, SYRE closed at 107.36, down from an intraday high of 110.15. The pullback is modest, but momentum is cooling.
SYRE — daily chart with candlesticks, EMA20/EMA50 and volume.Key takeaways
- SYRE closed Tuesday at 107.36, down from an intraday high of 110.15, after a roughly 565% twelve-month surge.
- The daily trend remains bullish with price above the EMA20 at 104.09, EMA50 at 96.81, and EMA200 at 66.64.
- The daily MACD shows a negative histogram of -0.14, indicating that upside thrust has softened.
- Daily ATR14 sits at 4.75, and short interest is 13.81% of float, supporting elevated two-sided risk.
- The bullish scenario requires reclaiming the daily pivot at 108.15, with resistance at 109.36.
Spyre Therapeutics Stock Daily Trend: Structure Still Favors the Bulls
The daily trend for Spyre Therapeutics stock still favors the bulls. Price trades well above the EMA20 at 104.09, the EMA50 at 96.81, and the EMA200 at 66.64. That stacked alignment is a textbook bullish structure. It confirms the primary trend since last year has not been broken. The daily regime reading is also labeled bullish, matching the price action.
However, momentum indicators tell a slightly more cautious story. The daily RSI14 sits at 59.12, which is firmly bullish but not overbought. More notably, the daily MACD shows a line of 2.93 against a signal of 3.07. That produces a negative histogram of -0.14. A subtle bearish crossover is forming just as price backed away from the highs. It does not break the uptrend, but it does suggest the upside thrust has softened.
Bollinger Bands and Pivot Context
Meanwhile, the Bollinger Bands add useful context. The daily mid-band sits at 103.88 and the upper band at 110.89. Tuesday’s high of 110.15 pushed right up against that upper boundary before fading. Price stretched into resistance and then retreated. This is common behavior after a strong run rather than a reversal signal on its own. The daily ATR14 of 4.75 confirms this is still a high-volatility name. Traders should expect wide daily ranges to continue.
At the same time, pivot levels reinforce the near-term battle zone. The daily pivot sits at 108.15, with resistance at 109.36 and support at 106.15. Tuesday’s close at 107.36 landed right in between, essentially in no-man’s-land.
SYRE 1H Timeframe: Confirmation Turns Into Hesitation
The hourly timeframe for SYRE remains bullish in structure, but it now shows clear momentum hesitation. The EMA20 at 107.4, EMA50 at 106.57, and EMA200 at 102.31 remain properly stacked. The regime is still tagged bullish. RSI14 on the 1H has dropped to 50.99. That neutral reading signals momentum has stalled rather than accelerated.
Therefore, the hourly MACD mirrors the daily conflict. The line reads 0.22 versus a signal of 0.3, producing a negative histogram of -0.08. Short-term momentum has clearly rolled over even as the broader hourly trend structure holds. This is a case where trend and momentum are not fully aligned. That conflict is worth watching rather than ignoring.
Still, Bollinger Bands on the 1H are tight, with the mid-band at 107.43 essentially matching the last close of 107.42. Price is compressing rather than trending. The ATR14 of 1.27 confirms intraday volatility has calmed compared to daily swings. The hourly pivot sits at 107.28, with resistance at 107.57 and support at 107.14. The stock is trapped inside a very narrow band right now.
15-Minute View: Execution Context
The 15-minute chart turns neutral and favors patience on entry timing. The regime flips to neutral, and short-term hesitation becomes most visible. Price at 107.42 sits just below the EMA20 at 107.54 and EMA50 at 107.59. It still holds above the EMA200 at 106.59. RSI14 at 47.32 leans slightly soft, while the MACD histogram is negative at -0.07. That reading matches the broader short-term stall on the hourly chart.
For traders using this window to time entries, the message is clear. The stock needs to reclaim the 107.5–107.7 zone to regain short-term control. Otherwise, consolidation toward the 106.5 area remains the path of least resistance intraday.
The Bullish Case for SYRE Stock
The bullish case for Spyre Therapeutics stock depends on reclaiming the daily pivot at 108.15. The scenario rests on the daily trend reasserting itself. A reclaim of 108.15 and a push through R1 at 109.36 would open the door back toward the upper Bollinger Band near 110.89. That would effectively retest the recent highs.
Additionally, the news flow supports that possibility. Spyre’s SPY772 program is now testing whether dual-pathway inhibition can broaden the company’s story beyond its core IBD franchise through the SKYLIGHT study. That could add a second growth pillar. Positive ulcerative colitis data has already fueled the stock’s 44.9% three-month rally. Upcoming clinical catalysts remain a genuine bullish catalyst.
Moreover, elevated short interest at 13.81% of float means any positive surprise could accelerate gains through short covering.
The Bearish Case and What Would Invalidate the Bullish Bias
The bearish case centers on momentum failing to recover and a loss of daily S1 support at 106.15. If the daily MACD histogram continues to widen negatively and price loses S1, the next real structural test becomes the EMA20 at 104.09. A break below that level would put the daily bullish regime itself in question. Even then, EMA50 and EMA200 would still sit far below as long-term support.
On the hourly chart, losing the 107.14 pivot support would also matter. If RSI continues to soften below 50, that would confirm short-term sellers are gaining control rather than simply pausing.
Notably, the Yahoo Finance piece on the stock’s 44.9% three-month rally flagged that its lofty valuation raises the stakes for upcoming readouts. Any disappointing clinical update could therefore trigger a sharper-than-usual correction given how far and fast SYRE has run.
Closing Take
Spyre Therapeutics stock remains bullish on the daily trend, but short-term momentum has cooled. The daily trend still favors buyers, while the 1H and 15-minute timeframes show clear hesitation. This is not a broken chart, but it is not a clean breakout signal either.
Overall, given the daily ATR14 of 4.75, volatility is likely to stay elevated regardless of direction. With short interest sitting near 13.81% of float, sharp moves in either direction remain plausible. Positioning here should account for that two-sided risk, especially with clinical catalysts from programs like SPY772 still ahead.
FAQ
Is Spyre Therapeutics stock still in an uptrend?
Yes. The daily trend remains bullish, with SYRE trading above the EMA20 at 104.09, EMA50 at 96.81, and EMA200 at 66.64. The daily regime reading is also labeled bullish.
Why is momentum cooling in Spyre Therapeutics stock?
The daily MACD shows a line of 2.93 against a signal of 3.07, producing a negative histogram of -0.14. Hourly RSI14 has dropped to 50.99, and the 15-minute regime has flipped to neutral.
What level must SYRE reclaim for the bullish case to strengthen?
The bullish scenario requires reclaiming the daily pivot at 108.15 and then pushing through resistance at 109.36. That would open a path back toward the upper Bollinger Band near 110.89.
What would invalidate the bullish bias?
A loss of the daily S1 support at 106.15 would put the EMA20 at 104.09 in focus. A break below that level would question the daily bullish regime, even with longer-term support still below.
Disclaimer: This article is for informational purposes only and does not constitute financial advice, an investment recommendation, or a solicitation to buy or sell any financial instrument or cryptocurrency. The analysis provided is not indicative of future results. Investing in crypto assets and financial markets carries a high risk of capital loss. Always do your own research (DYOR) and consult a qualified financial advisor before making any decision.
Article produced with the assistance of artificial intelligence and reviewed by the editorial team.
English (US) ·